Literature DB >> 8654603

Malignant ascites: a 2-year review from a teaching hospital.

S L Parsons1, M W Lang, R J Steele.   

Abstract

In this retrospective review of 164 consecutive patients with malignant ascites it has been shown that ovarian ascites accounts for 28% of the total and is associated with a significantly improved survival compared with other groups (P<0.001). Non-ovarian ascites is associated with a very poor prognosis and many patients in this group are unsuitable for aggressive treatment. In 49% of patients, ascites will be the presenting feature requiring further investigation to ascertain the primary tumour. Thorough investigation of female patients should be performed in order to identify all patients with an ovarian primary so that appropriate chemotherapy can be given. However, thorough investigation in male patients is not justifiable.

Entities:  

Mesh:

Year:  1996        PMID: 8654603     DOI: 10.1016/s0748-7983(96)80009-6

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  30 in total

1.  Role of malignant ascites on human mesothelial cells and their gene expression profiles.

Authors:  Isabelle Matte; Denis Lane; Dimcho Bachvarov; Claudine Rancourt; Alain Piché
Journal:  BMC Cancer       Date:  2014-04-24       Impact factor: 4.430

2.  A survey of treatment approaches of malignant ascites in Germany and Austria.

Authors:  C F Jehn; S Küpferling; G Oskay-Özcelik; D Lüftner
Journal:  Support Care Cancer       Date:  2014-12-21       Impact factor: 3.603

3.  Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites.

Authors:  Daye Cheng; Bin Liang; Hong Kong
Journal:  Med Oncol       Date:  2011-05-10       Impact factor: 3.064

4.  Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites.

Authors:  Nian Fang; Hui-Qing Zhang; Bo He; Mei Xie; Shan Lu; Yi-Ye Wan; Nong-Rong Wang
Journal:  Tumour Biol       Date:  2013-11-27

Review 5.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

6.  Palliative treatment of malignant ascites: profile of catumaxomab.

Authors:  Lila Ammouri; Eric E Prommer
Journal:  Biologics       Date:  2010-05-25

7.  How valuable is ascitic cytology in the detection and management of malignancy?

Authors:  R O S Karoo; T D R Lloyd; G Garcea; H D Redway; G S R Robertson
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

8.  Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications.

Authors:  Angel Mier Hicks; Joanne Chou; Marinela Capanu; Maeve A Lowery; Kenneth H Yu; Eileen M O'Reilly
Journal:  Clin Colorectal Cancer       Date:  2016-05-07       Impact factor: 4.481

Review 9.  Symptomatic Fluid Drainage: Tunneled Peritoneal and Pleural Catheters.

Authors:  Tony Ha; David C Madoff; David Li
Journal:  Semin Intervent Radiol       Date:  2017-12-14       Impact factor: 1.513

Review 10.  Treatment of malignant ascites.

Authors:  Michael Chung; Peter Kozuch
Journal:  Curr Treat Options Oncol       Date:  2008-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.